MedTrace Logo

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2020-12-21

No results posted yet for this study

Summary

A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy

Conditions

Interventions

DRUG

Vedolizumab

standard vedolizumab induction (300mg IV at week 0, 2, 6)

Sponsors & Collaborators

Principal Investigators

  • Aida Habtezion, MD · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2020-12-11
Completion
2020-12-11
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802214 on ClinicalTrials.gov